Introduction
Left ventricular ejection time (LVET) is defined by the opening and closing of the aortic valve, which in turn mainly is determined by the pressure differences across the valve. In the ailing heart, LVET will change during disease progression as previously demonstrated in patients with ischaemic heart disease, heart failure (HF), hypertension and aortic stenosis.
1 -3 As left ventricular (LV) function deteriorates, the ability of the heart to produce contractile force is attenuated and the rate of LV pressure rise (LV dP/dt) during the isovolumic contraction decreases, resulting in a prolongation of isovolumic contraction time. 4 -6 Furthermore, the ability of the ailing heart to maintain a high LV pressure during the ejection period decreases, resulting in reduction in LVET. 4 -6 Additionally, LVET will also shorten with LV deterioration simply as the result of the prolonged isovolumic contraction time which induces a delayed onset of ejection.
echocardiography. 9 The LVET has been demonstrated to identify impaired cardiac function in patients with ischaemic heart disease, 10 hypertension, 11 primary pulmonary hypertension 12, 13 and HF. 7, 14, 15 In addition, LVET has previously been demonstrated to be a strong predictor of cardiovascular outcome in selected patient populations, especially in patients with ischaemic heart disease 8,10,16 -19 and primary pulmonary hypertension, 12,13 but whether this measure has prognostic utility in a general population free of cardiovascular disease is unknown. In addition, it is not well understood which cardiovascular outcomes a shorter LVET is associated with.
Methods

Study population
The study population consists of the Jackson cohort of the Atherosclerosis Risk in Communities (ARIC) study. The ARIC study is an ongoing, prospective observational study of the natural history of atherosclerotic diseases and cardiovascular risk factors. Detailed study rationale, design, and procedures have been previously published. 20 The original cohort was recruited between 1987-1989 using probability sampling of middle aged (45-64 years old) men and women from four communities in the United States (Forsyth County, NC; Jackson, MS; Minneapolis, MN; and Washington County, MD). The Jackson field center enrolled an entirely African-American cohort, the Jackson cohort. Subsequent follow-up visits occurred at approximately 3-year intervals up to visit 4 (1996-1999) , with annual telephone interviews conducted between visits. Institutional review boards approved the study and informed consent was obtained from all participants.
Transthoracic echocardiography was performed only in the Jackson cohort during visit 3 (1993-1996) . Of 2445 participants who underwent transthoracic echocardiography, 2257 had LVET measured. After excluding participants with previous HF, missing HF data, and known coronary heart disease (n=277), our study population included 1980 participants.
Demographics
Hypertension, diabetes mellitus, coronary heart disease, stroke, smoking status, and medication use was defined as previously described in ARIC. 21 Estimated glomerular filtration rate, haematologic parameters, lipids, and glucose were measured according to standardized protocols.
Echocardiography
Echocardiograms were recorded by four trained sonographers and interpreted by experienced cardiologists in the Echocardiography Reading Center located at the University of Mississippi Medical Center. Two-dimensional, M-mode, and Doppler images were acquired with an Acuson 128XP/10c cardiac ultrasound machine with 2.5, 3.5, and 5.0 MHz transducers (Acuson, Malvern, PA, USA). Measurements were performed by the interpreting physician who was blinded to the participants' clinical data. Left ventricular end-diastolic diameter, LV end-systolic diameter, septal and posterior wall thickness, and left atrial diameter were measured from two-dimensional images according to the American Society of Echocardiography criteria. 22 The LVET was measured as the duration of the flow through the LV outflow 
Outcomes
The follow-up period was defined as the time elapsed from the date of echocardiography to the date of event, date of last contact for those lost to follow-up, or end of 2012. Incident HF was defined as the occurrence of a hospitalization with an ICD-9 discharge code 428 in any position or a death certificate with either an ICD-9 code 428 in any position or an ICD-10 code 150 in any position. Incident myocardial infarction (MI) was defined as definite or probable hospitalization for MI based on committee adjudication of abstracted hospitalization records including chest pain symptoms, electrocardiograms (ECGs), and cardiac enzymes. Death was ascertained by annual phone call follow-up or through health department death certificate files. 23 The composite outcome of incident HF, incident MI or death was also assessed.
Statistical analysis
Baseline characteristics across LVET quartiles were compared with trend tests [for continuous Gaussian distributed variables obtained by regression analysis, by an extension of the Wilcoxon rank-sum test 24 for continuous non-Gaussian distributed variables and by a chi-square test for proportions (Cochran-Armitage trend test)]. Rates of all events were calculated (number of events divided by person-time at risk) and stratified by quartiles of LVET. Hazard ratios (HRs) were calculated by Cox proportional hazards regression analyses using time since visit 3. The association between LVET, LVET/RR and outcomes was assessed using the variables as linear predictors. In addition, departure from linearity for the association between LVET and outcomes was tested using restricted cubic splines with the number of knots selected according to the value associated with the lowest Akaike information criterion value. The association was further assessed using a piecewise linear model, with separate linear relationships considered for set values <350 ms and for set values ≥350 ms. The predictive capabilities of LVET was assessed in a univariable model, an age and gender adjusted model, a model including the important demographic determinants of LVET (model 2a), a model including the variables included in the Framingham risk score (model 2b) and a model including the important demographic determinants of LVET and echocardiographic measures of systolic and diastolic function (model 3). Harrell's c-statistics 25 obtained from Cox proportional hazards regression models including the variables from the Framingham risk score 26 (age, gender, total cholesterol, HDL cholesterol, smoking status and systolic blood pressure) and the SCORE risk chart 27 (age, gender, cholesterol, smoking status and systolic blood pressure) were calculated and compared with the c-statistics obtained from Cox proportional hazards models also including LVET in order to test the incremental prognostic performance of the models when adding LVET to the parameters from the conventional risk scores. C-statistics were compared using a transformation of the equivalent Somers' D parameters. 28 Similarly, continuous and categorical net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were obtained when adding LVET to the parameters included in Framingham risk score using Cox models and 15 years of follow-up (Supplementary material online, Table S1 ). Collinearity and interaction was assessed for LVET and all covariates included in the final multivariable model (model 3). A P-value ≤0.05 in two-sided test 
Results
The population demographics stratified by quartiles of LVET are shown in Table 1 . Briefly, the participants had a mean age of 59±6 years, 36% (n=718) were males, 57% (n=1128) had hypertension, 22% (n=428) had diabetes, mean systolic and diastolic blood pressure were 140±20 mmHg and 82±10 mmHg, respectively, mean heart rate was 66±10 b.p.m., and mean LVET was 342±35 ms. Participants with a shorter LVET were younger, more likely male, had higher diastolic blood pressure, a higher proportion of diabetes, a higher heart rate, higher blood glucose levels, lower fractional shortening, and a larger LV end-systolic diameter ( Table 1) .
Systolic ejection time and outcome
During a median follow-up of 17.6 years, outcomes included 384 with incident HF (19%), 158 with MI (8%), and 587 were deceased (30% (Figure 2 and Table 2 ).
When assessing LVET as a continuous variable, decreasing LVET was significantly associated with increased risk of all outcomes, particularly for predicting incident HF (Figures 1 and 2; Table 3 ). After multivariable adjustment for age, gender, hypertension, diabetes, body mass index, heart rate, systolic and diastolic blood pressure, LVET remained an independent predictor of all outcomes ( Table 3) . When adjusting for our conventional measure of systolic and diastolic function, fractional shortening and left atrial diameter, LVET remained an independent predictor only of incident HF and the composite outcome ( Table 3) .
Incremental prognostic information obtained from left ventricular ejection time
The primary risk stratification models used for assessing risk of cardiovascular morbidity and mortality in the general population are currently the Framingham risk score 26 and the SCORE risk chart. 27 We assessed if adding LVET to the known risk factors obtained from these risk models (SCORE: age, gender, cholesterol, smoking status and systolic blood pressure and Framingham risk score: age, gender, total cholesterol, HDL cholesterol, smoking status and systolic blood pressure) would improve model performance. When adding LVET to the factors from the Framingham risk score 26 or the SCORE risk chart 27 Similar results were found when adding LVET to the Framingham risk score as assessed by continuous NRI and IDI. The addition of LVET to models using Framingham risk factors produced significant increases in IDI of approximately +1% and in continuous NRI of approximately +13% with respect to the primary outcome, death and HF. Categorical NRI was also significantly improved with respect to the primary outcome and HF (+3.0% and +4.8%, respectively; Supplementary material online, Table S1 ).
Discussion
In the present report we demonstrate the prognostic utility of LVET in a large general population free of cardiovascular disease using long-term follow-up. The LVET is a significant echocardiographic predictor of cardiovascular morbidity and mortality in a general population with no known cardiovascular disease. Additionally, LVET is primarily a strong predictor of incident HF, but not MI and to a lesser extent all-cause mortality. The LVET provided incremental prognostic information regarding risk of HF and all-cause mortality, but not MI, when added to the Framingham risk score or the SCORE risk chart.
Left ventricular ejection time and cardiovascular outcome
The LVET has previously been demonstrated to be a strong predictor of outcome, especially in patients with ischaemic heart disease 8,10,16 -19 and primary pulmonary hypertension. 12,13 In a previous report, LVET obtained by M-mode tissue Doppler imaging (TDI) was a univariable predictor of a combined outcome of ischaemic heart disease, HF, and cardiovascular mortality in a general population, 29 some of whom had a history of cardiovascular disease. With longer follow-up and therefore more events and higher statistical power, we were able to show that this relationship is mostly due to hospitalization for HF.
Weissler and colleagues demonstrated in 1968 that patients with HF had significantly shorter LVET and longer pre-ejection period (PEP defined as the Q-wave of the ECG -LVET from the central artery pulse) compared to normal individuals. LVET are mainly measures of systolic function, 4 and measures of systolic and diastolic function have previously been demonstrated to predict different outcomes. 30 In the general population, early systolic dysfunction determined by reduced myocardial systolic velocity (TDI s') or global longitudinal strain have been shown to be a strong predictor of HF 30,31 whereas a reduced diastolic function as determined by a reduced early diastolic relaxation velocity (TDI e') was a strong predictor of MI.
30 This is in accordance with our results where our measure of systolic function primarily predicted HF events and not MI or death ( Table 3) .
In particular, we found that it was in the low range of LVET that the risk of HF, all-cause mortality, and the combined endpoint increased, whereas a decreasing LVET in the high range was not associated with an increased risk (Tables 2 and 3; Figures 1  and 2 ). This phenomenon has been seen in previous studies.
16,29
Furthermore, judging from our results it seems that incident HF primarily drives this range specific pattern of risk obtained from LVET. This is very important because it indicates that there might be a specific cut-off where a decreasing LVET no longer is within the physiological normal range and is a marker of an ailing heart, which, if left untreated, might lead to HF. In the present report, the cut-off seems to be somewhere below 350 ms (Figures 1 and 2) . However, since there are many methods of obtaining LVET (pulsed wave Doppler of the LV outflow tract, 32 TDI velocity curves, 33 or M-mode TDI 16,29,34 -37 ) that lead to different absolute values, further studies are needed to assess the clinically useful cut-offs for each method.
Usefulness of left ventricular ejection time in clinical trials
The LVET is a very easy and fast measure to obtain with high reproducibility. 38, 39 In contrast to TDI and speckle tracking, LVET is measurable with all conventional echocardiographic machines and software and improves our current risk prediction models. The LVET has therefore been used for several decades to monitor LV contractility and function when testing new medical therapies. 6 In clinical trials, LVET has previously been demonstrated to improve with medical therapy in patients with ischaemic heart disease, 10 hypertension, 11 and HF. 14, 15 Recently, LVET was used as the primary echocardiographic outcome in a large, multicenter randomized trial 40 testing a novel drug (omecamtiv mecarbil) that specifically increases the duration of LVET in patients with HF.
14,15 Furthermore, the effect of intravenous administration of this drug on LVET was consistent in healthy volunteers, 41 chronic HF patients, 14 and acute HF patients, 42 as well as the oral study. 40 Even though the LVET has been around for several decades, the usefulness of this simple measure might therefore be revived within the near future. composition. Nevertheless, previous studies comprised primarily of Caucasians have shown that LVET is also predictive of cardiovascular outcomes in general populations with other compositions. However, in these previous studies, the association of LVET with the individual endpoints was not assessed as only the association with composite endpoints was evaluated. 29, 35 In addition, changes in therapies for hypertension and diabetes mellitus during the last two decades may influence the relevance of the results presented in this report to contemporary populations. Unfortunately, we were not able to assess whether the association between LVET and incident HF was derived from an association with HF with preserved or reduced ejection fraction, since the ICD-9 codes do not discriminate between the two types of HF admissions. In addition, natriuretic peptides were not measured in the Jackson cohort of the ARIC study. Incident HF occurred more often than MI and less often than death, hence, LVET had greatest power for detecting the association between LVET, HF and death. Furthermore, it should be noted that the Framingham risk score and the SCORE risk chart are both calibrated to predict risk of ischaemic cardiovascular events, which might also explain the finding that LVET did not provide incremental prognostic information regarding risk of MI when added to the known risk factors. Interestingly, despite the fact that these two models were not originally calibrated for incident HF, we found that the variables included in the Framingham risk model calibrated well to predict incident HF in the ARIC population as determined by a non-significant difference between predicted and observed number of outcomes (Grønnesby-Borgan chi-square statistic of 6.214 and corresponding P=0.72). We did not adjust for multiple comparisons. Like all other echocardiographic measures of systolic and diastolic function, LVET depends on heart rate. 43, 44 Hence, physicians should always take heart rate into account when assessing LVET.
Unfortunately, volumetric measurements were not performed as part of the echocardiographic examination of the Jackson cohort of the ARIC study. All measures of cardiac structure and function are therefore based on dimensional measures. Likewise, the PEP and the time interval between the late transmitral flow (A wave) and the early transmitral flow (E wave) of the following heart cycle were not measured; hence, we were not able to calculate neither the myocardial performance index nor the PEP/LVET in the present study. The fact that LVET is a strong predictor of incident HF using echocardiographic machines from 1993 demonstrates the generalizability and how easy it would be to implement in echocardiographic laboratories all around the world despite limited availability of the newest machines and software.
Conclusion
The LVET is a significant predictor of cardiovascular morbidity and mortality in a general population with no known cardiovascular disease. However, LVET is primarily a strong predictor of incident HF and not MI or all-cause mortality. Furthermore, LVET provides incremental prognostic information regarding risk of HF and all-cause mortality, but not MI, when added to the Framingham risk score or the SCORE risk chart.
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